title: PSA density (PSAD). Role in patient evaluation and management.
abstract: Prostate Specific Antigen (PSA) is the most accurate serum marker for cancer of the prostate. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml (monoclonal). For intermediate PSA levels, prostate specific antigen density (PSAD) provides unique information regarding the need for biopsy and the likelihood of prostate cancer. This article summarizes the utility of PSAD in diagnosing and treating prostate cancer.
authors.affiliation: Department of Urology, College of Physicians and Surgeons of Columbia University, New York, New York.
authors.forename: E
authors.initials: E
authors.lastname: Seaman
authors.forename: M
authors.initials: M
authors.lastname: Whang
authors.forename: C A
authors.initials: CA
authors.lastname: Olsson
authors.forename: A
authors.initials: A
authors.lastname: Katz
authors.forename: W H
authors.initials: WH
authors.lastname: Cooner
authors.forename: M C
authors.initials: MC
authors.lastname: Benson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen